Clinical Trial Update: Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation [Phase 4]

View source ↗

Summary

Clinical trial evaluating rivaroxaban 15 mg and 20 mg for efficacy and safety in patients with non-valvular atrial fibrillation (Phase 4). Recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Korea University Anam Hospital | Conditions: Atrial Fibrillation, Anticoagulant Adverse Reaction | Phase 4 | Status: RECRUITING